FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer
Approval is based on findings from the KEYNOTE‑177 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment
Efficacy was investigated in the JAVELIN Bladder 100 trial
EMA Recommends Refusal of the Marketing Authorisation for Pexidartinib
It was intended for the treatment of tenosynovial giant cell tumour
FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-positive Breast Cancer
Efficacy was investigated in FeDeriCa trial
Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions
Findings from a retrospective study presented at ESMO World GI 2020 Virtual
Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and Metastatic Pancreatic Cancer
Results from an additional analyses of phase III POLO trial by age group presented at ESMO World GI 2020 Virtual
Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma
Results of the CheckMate 459 study long-term survival outcomes presented at ESMO World GI 2020 Virtual
ESMO Releases New Patient Guide in Hepatocellular Carcinoma
A comprehensive new edition presents the latest information in early-, intermediate- and advanced-stage hepatocellular carcinoma
EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab
It is intended for the treatment of carcinoma of the colon or rectum, breast cancer, NSCLC, RCC, epithelial ovarian cancer, and carcinoma of the cervix
FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma
Evidence for efficacy is based on the results from the KEYNOTE-629 trial
Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs
More safety data is needed in terms of treatment of symptomatic COVID-19 patients with anticancer drugs
FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Approval is based on the results from the SADAL trial